[go: up one dir, main page]

NO951061L - Antistoffkonjugater med forbedrede egenskaper - Google Patents

Antistoffkonjugater med forbedrede egenskaper

Info

Publication number
NO951061L
NO951061L NO951061A NO951061A NO951061L NO 951061 L NO951061 L NO 951061L NO 951061 A NO951061 A NO 951061A NO 951061 A NO951061 A NO 951061A NO 951061 L NO951061 L NO 951061L
Authority
NO
Norway
Prior art keywords
improved properties
antibody conjugates
conjugate
mammal
human
Prior art date
Application number
NO951061A
Other languages
English (en)
Other versions
NO951061D0 (no
Inventor
Brendan Murray
Terence O'reilly
Gerd Pluschke
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of NO951061D0 publication Critical patent/NO951061D0/no
Publication of NO951061L publication Critical patent/NO951061L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Det blir beskrevet et oppløselig konjugat hvor et bæreprotein er kovalent bundet til et monoklonalt antistoff, et farmasøytisk preparat omfattende et slikt konjugat og en fremgangmsåte for fremstillingen derav. Et konjugat Ifølge oppfinnelsen er nyttig f.eks. for aktiv immunoterapi av et pattedyr, spesielt et menneske.
NO951061A 1994-03-21 1995-03-20 Antistoffkonjugater med forbedrede egenskaper NO951061L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP94810173 1994-03-21

Publications (2)

Publication Number Publication Date
NO951061D0 NO951061D0 (no) 1995-03-20
NO951061L true NO951061L (no) 1995-09-22

Family

ID=8218230

Family Applications (1)

Application Number Title Priority Date Filing Date
NO951061A NO951061L (no) 1994-03-21 1995-03-20 Antistoffkonjugater med forbedrede egenskaper

Country Status (11)

Country Link
JP (1) JPH0820545A (no)
KR (1) KR950031111A (no)
AU (1) AU1481795A (no)
CA (1) CA2144936A1 (no)
FI (1) FI951276L (no)
HU (1) HUT71776A (no)
IL (1) IL113022A (no)
NO (1) NO951061L (no)
NZ (1) NZ270734A (no)
RU (1) RU95104325A (no)
ZA (1) ZA952269B (no)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2865737B1 (fr) * 2004-02-03 2006-03-31 Anteis Sa Gel reticule biocompatible

Also Published As

Publication number Publication date
AU1481795A (en) 1995-09-28
JPH0820545A (ja) 1996-01-23
IL113022A0 (en) 1995-06-29
HUT71776A (en) 1996-01-29
KR950031111A (ko) 1995-12-18
ZA952269B (en) 1995-09-21
FI951276A0 (fi) 1995-03-17
FI951276A7 (fi) 1995-09-22
FI951276L (fi) 1995-09-22
IL113022A (en) 2000-02-29
HU9500586D0 (en) 1995-04-28
NZ270734A (en) 1997-05-26
RU95104325A (ru) 1996-12-27
CA2144936A1 (en) 1995-09-22
NO951061D0 (no) 1995-03-20

Similar Documents

Publication Publication Date Title
PT1135498E (pt) Variantes de anticorpos com maior afinidade de ligação em comparação com os anticorpos parentais
DK499086A (da) Konjugater af trichothecen og anvendelse af samme som terapeutisk substans
CO4850562A1 (es) Proceso para producir una preparacion concentrada de anticuerpos
EP4378958A3 (en) High-affinity anti-mertk antibodies and uses thereof
EP0724456A4 (en) ANTIBODIES AGAINST CD40
ATE383430T1 (de) Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren
PL248202A1 (en) Process for preparing conjugate with chain b of toxin and method of manufacture of cytotoxic composition
ATE267610T1 (de) Glykosylierte igg antikörper
EP0683234A4 (en) ANTIBODIES DIRECTED AGAINST -g (b) -AMYLOID OR A DERIVATIVE THEREOF AND ITS USE.
AU563356B2 (en) Conjugate of enzyme and antibody
AU628948B2 (en) Monoclonal antibodies (mabs) against tumor-associated antigens, the preparation and use thereof
DK0969873T3 (da) Multiple carbonhydratholdige glycopeptid-antigener, vaccine indeholdende dem og anvendelse deraf
PT97423A (pt) Processo para a preparacao de composicoes farmaceuticas contendo conjugados de anticorpos para o tratamento de neoplasias
EP0350690A3 (de) Neutralisation der in vitro- und in vivo-toxischen Eigenschaften von TNF-alfa durch monoklonale Antikörper und die davon abgeleiteten Fragmente
IS4922A (is) Fjölpeptíð sem geta myndað formgerðir mótefnisvakabindinga með sérvirkni fyrir resus D mótefnisvaka, DNA-ið sem táknar þau og aðferðin til að búa þautil og notkun
DE69328779D1 (de) Benzodiazepin-derivate sowie deren konjugate mit proteinen und polypeptiden
NO951061L (no) Antistoffkonjugater med forbedrede egenskaper
ES2082132T3 (es) Composicion que contiene al menos dos anticuerpos distintos o fragmentos de ellos.
DE69611037D1 (de) Methadonderivate und protein- und polypeptid-methadonkonjugate und markierte verbindungen
Fodstad et al. New indirect approach to the therapeutic use of immunotoxins
DK0513565T3 (da) Monoklonale antistoffer mod plasmin-antiplasmin-komplekset, fremgangsmåde til deres fremstilling og deres anvendelse
IL139571A0 (en) A humanized antibody that binds to verotoxin, methods for the production thereof and pharmaceutical compositions containing the same
AU3637195A (en) Broadly reactive opsonic antibodies reactive with common staphylococcal antigens
DK0889907T3 (da) Monoklonale antistoffer, som binder humant væksthormon (hGH)
JPH0469345A (ja) 腫瘍細胞の除去方法